SAL 200

Drug Profile

SAL 200

Alternative Names: N-Rephasin® SAL200; SAL200

Latest Information Update: 04 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator iNtRON biotechnology
  • Developer iNtRON Biotechnology
  • Class Antibacterials; Coliphages; Endolysins; Endopeptidases; Proteins
  • Mechanism of Action Cell wall inhibitors; Peptidoglycan modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Methicillin-resistant Staphylococcus aureus infections
  • No development reported Vancomycin-resistant Staphylococcus aureus infections

Most Recent Events

  • 07 Mar 2017 Phase-II clinical trials in Methicillin-resistant Staphylococcus aureus infections in South Korea (IV) (NCT03089697)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Vancomycin-resistant-Staphylococcus-aureus-infections in South Korea (IV, Infusion)
  • 14 Aug 2014 SAL 200 is available for licensing as of 11 Aug 2014. www.intron.co.kr
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top